Welcome to GSTS Pathology

We are the UK's leading independent provider of Pathology Services, pairing the scientific expertise of two leading London teaching hospitals, Guys and St Thomas' and King's College Hospital, with the efficiency and excellence of Serco, an international FTSE100 organisation providing essential services to millions of people worldwide.

We are an exemplar of public private partnership in the health sector and our established clinical excellence and strong business acumen attracts the best people, and you can trust us to handle your requirements effectively, safely and efficiently.

4 sites | 1,000 employees | 14m tests each year

New Tests

Anti-TNF Drugs (Biologics)

The Reference Chemistry Laboratory at GSTS Pathology, Guy’s and St Thomas’ Hospital is the first to introduce anti-TNFα and anti-drug antibody testing in the UK. Our service is backed by innovative re-search in collaboration with the Gastroenterology and Dermatology clinical teams at GSTT. The introduc-tion of anti-TNFα drug and anti-drug antibody monitoring now allows clinician... 

Rapid TB molecular assay

Infection Sciences now offer the Cepheid GeneXpert MTB/RIF rapid molecular test that simultaneously identifies Mycobacterium Tuberculosis (MTB) and resistance to rifampicin (RIF). A 24 hour turnaround time is available for this test which can be performed on smear positive respiratory samples.

C.Difficile Molecular Gene Expert Assay

The Infection and Immunology labs have recently introduced the C.Difficile Molecular Gene Expert Assay which increases assay sensitivity and clinical relevance. This enables effective infection control and compliance with national targets.  

Next Generation Sequencing

The DNA laboratory is developing assays using Next Generation Sequencing (NGS) to screen for heterogeneous genetic disorders. These assays can be used to test a large number of genes simultaneously, thereby avoiding sequential gene testing. This will significantly improve the speed and reduce the overall cost of the molecular investi... 

Clostridium difficile

The Infection and Immunology department at GSTS is introducing a new screening protocol for Clostridium difficile from 1 September. The new protocol offers improved sensitivity and specificity through utilisation of state of the art molecular confirmation of toxigenic strains.

Active Vitamin B12 (holotranscobalamin)

The Nutristasis Unit now provides the new Active B12 (holotranscobalamin) marker and GSTS is the first provider in the UK to offer it outside the research environment. 

The majority (up to 80%) of serum vitamin B12 is not bio-available. Current assays measure total vitamin B12 which leads to a grey area where deficient patients can be mi... 

December's Innovation Academy

Featured Item

►CLICK HERE FOR PRESENTATIONS. The second Innovation Academy Symposium was held on 6th December 2013 at The Royal Institution of Great Britain, London. The theme for the event was ‘Personalised medicine: Today’s reality, not just a promise for tomorrow’.

Experts in clinical science presented examples of where diagnostics are already in use to provide personalised treatment.  The talks formed three streams: therapeutic drug monitoring, infectious disease and transplantation medicine, and oncology. ►CLICK HERE FOR MORE INFORMATION.

GSTS offering Active B12 test

Featured Item

GSTS Pathology is one of few pathology provider in the UK to perform the new Active B12 (holotranscobalamin) test for vitamin B12 deficiency. The new early marker complements GSTS' serum methylmalonic acid assay which is a functional marker of B12 and is more effective in picking up vitamin B12 deficiency than other current assays. 

For more information on the Active B12 assay visit the New Test page or contact John Roberts. 


GSTS offering ovarian cancer test

Featured Item

With recent calls from the National Institute for Health and Clinical Excellence (NICE) that women should be offered a blood test for ovarian cancer, GSTS reiterates that its Blood Sciences Department performs the CA-125 test for ovarian cancer.

To learn more about the CA-125 test at GSTS, contact Head of Blood Sciences, George Worthington.

More details on the NICE announcement can be found on the NICE website and the BBC website.

A-Z Test index

GSTS Pathology provides a constantly growing portfolio of tests to our customers and we perform more than seven million tests each year. To find a specific test, enter a keyword below, or to view all the tests GSTS provides visit the A-Z Test Index.